UNSPSC 51343308: Telinavir

This classification denotes a protease inhibitor with the molecular formula C33H44N6O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IZF55EH3CG, chemically known as butanediamide, n1-(3-((((1,1-dimethylethyl)amino)carbonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (1s-(1r*,(r*),2s*))- but generally known as telinavir, which bears US NIH Compound Identifier 60874.

UNSPSC 51343308 Telinavir, a Commodity code, does not align with the recent state and local opportunities tagged under it. The code nominally refers to a specific antiviral pharmaceutical, yet the recent solicitations show procurement activity for naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, emergency medical supplies, and generic multi-source pharmaceuticals and OTC products — none of which are telinavir. State and local governments buying under this code designation are actually sourcing a broad range of pharmaceuticals, medical consumables, and pharmacy benefit services rather than a single antiviral agent. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), municipal fire departments (City of Tampa), and multistate cooperative purchasing alliances (MMCAP, Minnesota Department of Administration), reflecting a mix of direct government procurement and coordinated purchasing across multiple jurisdictions.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Representative opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023; the Texas Health and Human Services Commission's RFI (HHS0017013) posted April 3, 2026, exploring direct-to-manufacturer prescription programs; the City of Tampa's IFB for 169 line items of medical and first aid supplies for the Tampa Fire Department with a response deadline of March 13, 2026 and an estimated contract value of $700,000; and MMCAP's RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026. The mismatch between the code name and actual procurement scope suggests either a misclassification in the source data or that telinavir is no longer a primary buying category under this code designation.